SRPT News & Events

The Dow Jones closed slightly in positive territory, while the S&P 500 and Nasdaq were sharply higher after the April jobs report beat forecasts. Chip stocks rebounded after yesterday's pause, helping lift the Nasdaq back toward record territory. Oil briefly pushed back above $100 after renewed U.S.-Iran clashes in the Strait of Hormuz, but equities have largely treated each flare-up as temporary noise.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Nvidiawillin Irenand announced a partnership between the two companiesExpediareported, affirmed its FY26 revenue guidance, and announced a new $5B stock buyback authorizationAkamaireportedand provided its outlook for Q2 and FY26Blockprovided areport for Q1President Trump has signed off on a plan to fire Food and Drug Administration Commissioner Marty Makary,2. WALL STREET CALLS:BofAHubSpotto Underperform, while Citi, William Blair and Cantor Fitzgerald also downgraded HubSpot to Neutral-equivalent ratings after the company's Q1 results and commentaryDaiwaQualcommto OutperformWells FargoNiketo Equal WeightMorgan Stanley, TD Cowen and BofAPlanet Fitnessto Neutral-equivalent ratingsCraig-HallumAkamaito Buy3. AROUND THE WEB:PG&Ereleased an inquiry saying it was aware of damage at the Mission substation responsible for a December blackout in San Francisco but left the damaged equipment in place, SF Standard reportsAnthropic reached a cloud computing deal with Akamai, Bloomberg saysMeanwhile, Anthropic is weighing a deal for a nearly $1T valuation, FT reportsMeta'sAI push is causing anger and anxiety among the company's employees, NY Times reportsThe U.S. suspects Nvidiachips were smuggled tot Alibabavia Thailand, Bloomberg reports4. MOVERS:Monster Beverageadvanced after reportingArlo Technologiesrose afterand reiterating its FY26 outlookRocket Lab USAgained after providing anCloudflarefell after providing areport but also announcing 1,100 layoffsCoreWeavedeclined after reporting5. EARNINGS/GUIDANCE:Toyotareported a year-over-yearYelpand reiterated its FY26 revenue outlookGrouponreportedCoinbasereported a sharp drop inWendy'sreportedINDEXES:The Dow rose 12.19, or 0.025%, to 49,609.16, the Nasdaq gained 440.88, or 1.71%, to 26,247.08, and the S&P 500 advanced 61.82, or 0.84%, to 7,398.93.

President Trump has signed off on a plan to fire Food and Drug Administration Commissioner Marty Makary, following a tumultuous period for the regulator that included clashes over vaping, abortion and drug policy, The Wall Street Journal's Liz Essley Whyte reports, citing people familiar with the matter. Makary is seen by other top administration leaders as struggling to manage his agency, sparring frequently with health department officials and at times the White House, the author notes. Biotech stocks that could be impacted by the news include Moderna (MRNA), Sarepta (SRPT), Xencor (XNCR), PTC Therapeutics (PTCT), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Design Therapeutics (DSGN), Ultragenyx (RARE), Avidity Biosciences (RNA), Dyne Therapeutics (DYN), Wave Life Sciences (WVE), MeiraGTx (MGTX), uniQure (QURE), Regenxbio (RGNX), Novavax (NVAX) and Lexeo Therapeutics (LXEO).

Reports Q1 revenue $730.8M, consensus $475.01M. "We entered 2026 with clear priorities-stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta's next era. In the first quarter, we made meaningful progress against each," said Doug Ingram, chief executive officer, Sarepta Therapeutics. "Our commercial portfolio has begun to stabilize, supported by expanded field engagement and a growing body of evidence reinforcing the disease-modifying impact of ELEVIDYS, which we believe is positioned to return to growth. At the same time, we are advancing Cohort 8 of the ENDEAVOR study with sirolimus pretreatment to serve our goal of once again making ELEVIDYS available to the non-ambulatory community. Finally, we remain in a position of financial strength, with positive earnings, and continued cash flow generation that enables us to fully fund our pipeline. Our potentially best-in-class clinical-stage siRNA portfolio continues to advance, with encouraging early signals in DM1 and FSHD and multiple upcoming readouts across high-value programs."